Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Avasimibe Pfizer.

John R Burnett1, Murray W Huff

  • 1Department of Core Clinical Pathology & Biochemistry, Division of Laboratory Medicine, Royal Perth Hospital, Wellington Street, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Expert opinion on emerging drugs·2026
Same author

<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insights.

Expert opinion on investigational drugs·2026
Same author

From cells to organism: Impact of dyslipidemia on inwardly rectifying K<sup>+</sup> channels and cerebral vascular function.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2025
Same author

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Assessing the clinical progress of muvalaplin for reducing lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Emerging ANGPTL3-directed therapies for hyperlipidemia: insights from two recent phase II trials.

Expert opinion on investigational drugs·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Avasimibe, a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitor, is being developed to treat hyperlipidemia and atherosclerosis. This lipid-regulating agent is currently in phase III clinical trials.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Hyperlipidemia and atherosclerosis are significant cardiovascular risk factors.
  • Acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) plays a role in cholesterol metabolism.
  • Targeting ACAT is a potential therapeutic strategy for lipid disorders.

Purpose of the Study:

  • To evaluate the efficacy and safety of Avasimibe as a lipid-regulating agent.
  • To investigate the potential of Avasimibe in treating hyperlipidemia and atherosclerosis.

Main Methods:

  • Avasimibe (CI-1011/PD-148515) is a selective ACAT inhibitor.
  • The compound is undergoing rigorous phase III clinical trials.
  • Lipid profiles and atherosclerotic markers are assessed.

Related Experiment Videos

Main Results:

  • Avasimibe demonstrates selective inhibition of ACAT.
  • Clinical trial data is being gathered to assess therapeutic effects.
  • Ongoing trials will determine the compound's efficacy in managing lipid levels.

Conclusions:

  • Avasimibe shows promise as a novel therapeutic agent for hyperlipidemia and atherosclerosis.
  • Further results from phase III trials are anticipated to confirm its clinical utility.
  • The development of ACAT inhibitors like Avasimibe represents a significant advancement in cardiovascular pharmacotherapy.